Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide…
Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0)…
Leading Contract Research Organization integrates H1’s Trial Landscape platform to optimize global site selection, enhance diversity efforts, and streamline operational…
HUNTINGTON BEACH, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ACC Medlink, a leading provider of long-distance medical transportation services, proudly…
WINTER PARK, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition is thrilled to announce the opening of its inaugural…
RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without…
Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical…
Fischer Imaging Delivers MammoCAT to Johns Hopkins University for Preclinical TestingATLANTA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Mammograms are one…
New collaboration showcases successful integration of Ori's IRO Platform with Cue and Lovo processing systems to enhance efficiency in CGT…
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation…